HDAC1 is a required cofactor of CBFb-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia

Lisa E. Richter, Yiqian Wang, Michelle E. Becker, Rachel A. Coburn, Jacob T. Williams, Catalina Amador, R. Katherine Hyde

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Acute myeloid leukemia (AML) is a neoplastic disease characterized by the uncontrolled proliferation and accumulation of immature myeloid cells. A common mutation in AML is the inversion of chromosome 16 [inv (16)], which generates a fusion between the genes for core binding factor beta (CBFB) and smooth muscle myosin heavy chain gene (MYH11), forming the oncogene CBFB-MYH11. The expressed protein, CBFb-SMMHC, forms a heterodimer with the key hematopoietic transcription factor RUNX1. Although CBFb-SMMHC was previously thought to dominantly repress RUNX1, recent work suggests that CBFb-SMMHC functions together with RUNX1 to activate transcription of specific target genes.However, the mechanismof this activity or a requirement for additional cofactors is not known. Here, we show that the epigenetic regulator histone deacetylase 1 (HDAC1) forms a complex with CBFb-SMMHC, colocalizes with RUNX1 and CBFb-SMMHC on the promoters of known fusion protein target genes, and that Hdac1 is required for expression of these genes. These results imply that HDAC1 is an important component of the CBFb-SMMHC transcriptional complex, and that leukemia cells expressing the fusion protein may be sensitive to treatment with HDAC1 inhibitors. Using a knock-in mouse model expressing CBFb- SMMHC, we found that in vivo treatment with the HDAC1 inhibitor entinostat decreased leukemic burden, and induced differentiation and apoptosis of leukemia cells. Together, these results demonstrate that HDAC1 is an important cofactor of CBFb-SMMHC and a potential therapeutic target in inv (16) AML.

Original languageEnglish (US)
Pages (from-to)1241-1252
Number of pages12
JournalMolecular Cancer Research
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Histone Deacetylase 1
Acute Myeloid Leukemia
Core Binding Factor beta Subunit
Chromosomes, Human, Pair 16
Histone Deacetylase Inhibitors
Leukemia
Smooth Muscle Myosins
Therapeutics
Proteins
Myosin Heavy Chains
Cell Fusion
Gene Fusion
Myeloid Cells
Oncogenes
Epigenomics
Genes
Transcription Factors
Apoptosis
Gene Expression
Mutation

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

HDAC1 is a required cofactor of CBFb-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia. / Richter, Lisa E.; Wang, Yiqian; Becker, Michelle E.; Coburn, Rachel A.; Williams, Jacob T.; Amador, Catalina; Hyde, R. Katherine.

In: Molecular Cancer Research, Vol. 17, No. 6, 01.06.2019, p. 1241-1252.

Research output: Contribution to journalArticle

Richter, Lisa E. ; Wang, Yiqian ; Becker, Michelle E. ; Coburn, Rachel A. ; Williams, Jacob T. ; Amador, Catalina ; Hyde, R. Katherine. / HDAC1 is a required cofactor of CBFb-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia. In: Molecular Cancer Research. 2019 ; Vol. 17, No. 6. pp. 1241-1252.
@article{fc6a692df28c497d88f87521df269ad5,
title = "HDAC1 is a required cofactor of CBFb-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia",
abstract = "Acute myeloid leukemia (AML) is a neoplastic disease characterized by the uncontrolled proliferation and accumulation of immature myeloid cells. A common mutation in AML is the inversion of chromosome 16 [inv (16)], which generates a fusion between the genes for core binding factor beta (CBFB) and smooth muscle myosin heavy chain gene (MYH11), forming the oncogene CBFB-MYH11. The expressed protein, CBFb-SMMHC, forms a heterodimer with the key hematopoietic transcription factor RUNX1. Although CBFb-SMMHC was previously thought to dominantly repress RUNX1, recent work suggests that CBFb-SMMHC functions together with RUNX1 to activate transcription of specific target genes.However, the mechanismof this activity or a requirement for additional cofactors is not known. Here, we show that the epigenetic regulator histone deacetylase 1 (HDAC1) forms a complex with CBFb-SMMHC, colocalizes with RUNX1 and CBFb-SMMHC on the promoters of known fusion protein target genes, and that Hdac1 is required for expression of these genes. These results imply that HDAC1 is an important component of the CBFb-SMMHC transcriptional complex, and that leukemia cells expressing the fusion protein may be sensitive to treatment with HDAC1 inhibitors. Using a knock-in mouse model expressing CBFb- SMMHC, we found that in vivo treatment with the HDAC1 inhibitor entinostat decreased leukemic burden, and induced differentiation and apoptosis of leukemia cells. Together, these results demonstrate that HDAC1 is an important cofactor of CBFb-SMMHC and a potential therapeutic target in inv (16) AML.",
author = "Richter, {Lisa E.} and Yiqian Wang and Becker, {Michelle E.} and Coburn, {Rachel A.} and Williams, {Jacob T.} and Catalina Amador and Hyde, {R. Katherine}",
year = "2019",
month = "6",
day = "1",
doi = "10.1158/1541-7786.MCR-18-0922",
language = "English (US)",
volume = "17",
pages = "1241--1252",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - HDAC1 is a required cofactor of CBFb-SMMHC and a potential therapeutic target in inversion 16 acute myeloid leukemia

AU - Richter, Lisa E.

AU - Wang, Yiqian

AU - Becker, Michelle E.

AU - Coburn, Rachel A.

AU - Williams, Jacob T.

AU - Amador, Catalina

AU - Hyde, R. Katherine

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Acute myeloid leukemia (AML) is a neoplastic disease characterized by the uncontrolled proliferation and accumulation of immature myeloid cells. A common mutation in AML is the inversion of chromosome 16 [inv (16)], which generates a fusion between the genes for core binding factor beta (CBFB) and smooth muscle myosin heavy chain gene (MYH11), forming the oncogene CBFB-MYH11. The expressed protein, CBFb-SMMHC, forms a heterodimer with the key hematopoietic transcription factor RUNX1. Although CBFb-SMMHC was previously thought to dominantly repress RUNX1, recent work suggests that CBFb-SMMHC functions together with RUNX1 to activate transcription of specific target genes.However, the mechanismof this activity or a requirement for additional cofactors is not known. Here, we show that the epigenetic regulator histone deacetylase 1 (HDAC1) forms a complex with CBFb-SMMHC, colocalizes with RUNX1 and CBFb-SMMHC on the promoters of known fusion protein target genes, and that Hdac1 is required for expression of these genes. These results imply that HDAC1 is an important component of the CBFb-SMMHC transcriptional complex, and that leukemia cells expressing the fusion protein may be sensitive to treatment with HDAC1 inhibitors. Using a knock-in mouse model expressing CBFb- SMMHC, we found that in vivo treatment with the HDAC1 inhibitor entinostat decreased leukemic burden, and induced differentiation and apoptosis of leukemia cells. Together, these results demonstrate that HDAC1 is an important cofactor of CBFb-SMMHC and a potential therapeutic target in inv (16) AML.

AB - Acute myeloid leukemia (AML) is a neoplastic disease characterized by the uncontrolled proliferation and accumulation of immature myeloid cells. A common mutation in AML is the inversion of chromosome 16 [inv (16)], which generates a fusion between the genes for core binding factor beta (CBFB) and smooth muscle myosin heavy chain gene (MYH11), forming the oncogene CBFB-MYH11. The expressed protein, CBFb-SMMHC, forms a heterodimer with the key hematopoietic transcription factor RUNX1. Although CBFb-SMMHC was previously thought to dominantly repress RUNX1, recent work suggests that CBFb-SMMHC functions together with RUNX1 to activate transcription of specific target genes.However, the mechanismof this activity or a requirement for additional cofactors is not known. Here, we show that the epigenetic regulator histone deacetylase 1 (HDAC1) forms a complex with CBFb-SMMHC, colocalizes with RUNX1 and CBFb-SMMHC on the promoters of known fusion protein target genes, and that Hdac1 is required for expression of these genes. These results imply that HDAC1 is an important component of the CBFb-SMMHC transcriptional complex, and that leukemia cells expressing the fusion protein may be sensitive to treatment with HDAC1 inhibitors. Using a knock-in mouse model expressing CBFb- SMMHC, we found that in vivo treatment with the HDAC1 inhibitor entinostat decreased leukemic burden, and induced differentiation and apoptosis of leukemia cells. Together, these results demonstrate that HDAC1 is an important cofactor of CBFb-SMMHC and a potential therapeutic target in inv (16) AML.

UR - http://www.scopus.com/inward/record.url?scp=85067215127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067215127&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-18-0922

DO - 10.1158/1541-7786.MCR-18-0922

M3 - Article

C2 - 30814129

AN - SCOPUS:85067215127

VL - 17

SP - 1241

EP - 1252

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 6

ER -